Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

featured

Published in Metastatic Breast Cancer

Expert Opinion / Cases · November 30, 2022

Concurrent Recurrent Metastatic Breast Cancer With Lung Sarcoidosis

Written by: Jing Xi MD, MPH

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Discuss This item Follow

Susan Sadighi

Nov 30, 2022

Based on imaging and tumor marker reports, I believed letrozole worked very well in this case. We can preserve CDK 4/6 Inh. if the metastases show progression. Since the patient has no symptoms and we can not exclude lung metastasis, I do not agree with neck radiation too.

Amiy Arnav

Jan 07, 2023

In view of the prolonged disease-free survival and good response to Letrozole, I will suggest continuing the current management and reserve CDK4/6 Inhb for progression. Radiation may not be of much use to us.

Sep 28, 2023

Pending Moderator approval.
Delete

Metastatic Breast Cancer

Concurrent Recurrent Metastatic Breast Cancer With Lung Sarcoidosis

Discuss This item Follow

Susan Sadighi

Amiy Arnav

Further Reading

Outcomes of Neratinib + Fulvestrant + Trastuzumab and Biomarker Analysis in Patients With HR+/HER2−, HER2-Mutant MBC

Utility of a Risk-Stratification Model for Predicting Overall Survival Outcomes in Young Women With Stage IV Breast Cancer

Impact of a Bone-Targeted Therapy Regimen on Skeletal-Related Events in Patients With MBC and Bone Metastasis Surviving Longer Than 2 Years

Outcomes of ctDNA Analysis in Patients With HR+/HER2− Advanced Breast Cancer Treated With Ribociclib Plus Endocrine Therapy

Impact of First-Cycle Neutropenia and Dose Reduction on the Outcomes in Patients With HR+/HER2− MBC Treated With First-Line Palbociclib and Hormonal Therapy

Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in HER2-Expressing Metastatic Breast Cancer

Evaluating Low HER2 Status in Invasive Breast Carcinoma via HER2 Immunohistochemistry, With HER2 FISH Correlation

Initial Pertuzumab Plus Trastuzumab ± Chemotherapy Followed by Trastuzumab Plus Emtansine for ERBB2+ Metastatic Breast Cancer

Metastatic HR+/HER2− Breast Cancer With Co-Existing ESR1 and PIK3CA Mutation

Provider and Patient Perspectives Regarding Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2− Advanced Breast Cancer

The Dynamics of HER2-Low Expression During Breast Cancer Progression

Recently Updated